Skip to main content

Table 1 Clinical characteristics of participants

From: The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease

  Patient group vs control group Patient group
Controls (N = 26) Patients (N = 74) P aMCI (N = 35) AD (N = 39) P
Female (%) 21 (80.8%) 52 (70.3%) 0.30 23 (65.7%) 29 (74.4%) 0.42
Age (year) 68.7 ± 4.2 76.7 ± 8.5 < 0.001 75.6 ± 8.4 77.7 ± 8.5 0.30
Body mass index 23.7 ± 3.3 24.4 ± 3.4 0.38 24.5 ± 3.2 24.3 ± 3.7 0.82
Education (year) 11.4 ± 4.2 8.8 ± 4.9 0.02 9.2 ± 5.1 8.4 ± 4.7 0.51
First MMSE 28.4 ± 0.8 23.9 ± 5.8 < 0.001 26.9 ± 2.3 21.2 ± 6.7 < 0.001
 24–30 26 (100.0%) 50 (67.6%) 0.011 32 (91.4%) 18 (46.2%) < 0.001
 19–23 0 (0.0%) 11 (14.9%)   3 (8.6%) 8 (20.5%)  
 10–18 0 (0.0%) 12 (16.2%)   0 (0%) 12 (30.8%)  
 0–9 0 (0.0%) 1 (1.4%)   0 (0%) 1 (2.6%)  
Second MMSE 28.4 ± 1.5 22.9 ± 5.8 < 0.001 26.5 ± 2.0 19.7 ± 6.2 < 0.001
Hopkins Verbal Learning Test 23.4 ± 3.7 15.0 ± 4.9 < 0.001 16.7 ± 4.4 13.5 ± 4.9 0.005
Forward digit span 11.7 ± 1.7 9.0 ± 2.6 < 0.001 9.3 ± 2.5 8.6 ± 2.6 0.26
Backward digit span 7.2 ± 2.7 3.8 ± 2.4 < 0.001 4.7 ± 2.3 3.0 ± 2.1 0.001
Trail Making Test Part A 56.7 ± 25.6 115.3 ± 86.5 < 0.001 87.6 ± 67.7 140.2 ± 94.5 0.007
Clinical Dementia Rating 0.04 ± 0.14 1.05 ± 0.72 < 0.001 0.50 ± 0.00 1.54 ± 0.68 < 0.001
Apolipoprotein E ε2:ε3:ε4 7:12:7 (27%:46%:27%) 9:50:15 (12%:68%:20%) 0.109 2:28:5 (6%:80%:14%) 7:22:10 (18%:56%:26%) 0.084
  1. Data are presented as mean ± standard deviation or frequency (percentage)
  2. Abbreviation: aMCI mild cognitive impairment due to Alzheimer’s disease, AD Alzheimer’s disease, MMSE Mini-Mental State Examination